BioCentury
ARTICLE | Clinical News

Orbactiv oritavancin regulatory update

April 13, 2015 7:00 AM UTC

The European Commission approved IV Orbactiv oritavancin from The Medicines Co. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive bacteria, including methic...